The estimated Net Worth of Mark L. Jacobson is at least $5.44 million dollars as of 9 August 2024. Mr Jacobson owns over 47,739 units of Axsome Therapeutics Inc stock worth over $4,872,108 and over the last 5 years he sold AXSM stock worth over $0. In addition, he makes $570,000 as COO & Sec. at Axsome Therapeutics Inc.
Sign up
Mr Jacobson AXSM stock SEC Form 4 insiders trading
Mr has made over 3 trades of the Axsome Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 47,739 units of AXSM stock worth $192,866 on 9 August 2024.
The largest trade he's ever made was exercising 47,739 units of Axsome Therapeutics Inc stock on 9 August 2024 worth over $192,866. On average, Mr trades about 9,566 units every 14 days since 2020. As of 9 August 2024 he still owns at least 53,522 units of Axsome Therapeutics Inc stock.
You can see the complete history of Mr Jacobson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Mark L. Jacobson biography
Mark L. Jacobson is the COO & Sec. at Axsome Therapeutics Inc.
What is the salary of Mr Jacobson?
As the COO & Sec. of Axsome Therapeutics Inc, the total compensation of Mr Jacobson at Axsome Therapeutics Inc is $570,000. There are 4 executives at Axsome Therapeutics Inc getting paid more, with Herriot Tabuteau having the highest compensation of $4,715,750.
How old is Mr Jacobson?
Mr Jacobson is 38, he's been the COO & Sec. of Axsome Therapeutics Inc since . There are 10 older and 3 younger executives at Axsome Therapeutics Inc. The oldest executive at Axsome Therapeutics Inc is David Marek, 55, who is the Chief Commercial Officer.
What's Mr Jacobson's mailing address?
Mark's mailing address filed with the SEC is C/O AXSOME THERAPEUTICS, INC., ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK, NY, 10007.
Insiders trading at Axsome Therapeutics Inc
Over the last 9 years, insiders at Axsome Therapeutics Inc have traded over $3,013,485 worth of Axsome Therapeutics Inc stock and bought 82,512 units worth $1,366,003 . The most active insiders traders include Roger Jeffs, Susan Mahony et Mark Coleman. On average, Axsome Therapeutics Inc executives and independent directors trade stock every 114 days with the average trade being worth of $1,405,685. The most recent stock trade was executed by Mark E Saad on 11 September 2024, trading 11,016 units of AXSM stock currently worth $40,429.
What does Axsome Therapeutics Inc do?
axsome therapeutics is a biopharmaceutical company developing novel therapies for the treatment of cns disorders. axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. the company is based in new york city.
What does Axsome Therapeutics Inc's logo look like?
Complete history of Mr Jacobson stock trades at Axsome Therapeutics Inc
Axsome Therapeutics Inc executives and stock owners
Axsome Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Herriot Tabuteau,
Chairman of the Board, President, Chief Executive Officer, Founder -
David Marek,
Chief Commercial Officer -
Nick Pizzie,
Chief Financial Officer -
Dr. Herriot Tabuteau M.D.,
Founder, Chairman, CEO & Pres -
Mark L. Jacobson,
COO & Sec. -
Nick Pizzie CPA, M.B.A.,
Chief Financial Officer -
Roger Jeffs,
Lead Independent Director -
Mark Saad,
Independent Director -
Mark Coleman,
Independent Director -
Amanda Jones,
Senior Vice President - Clinical Research -
Cedric O'Gorman,
Senior Vice President - Clinical Development and Medical Affairs -
Mark Jacobson,
Chief Operating Officer -
Joseph Debrah-Afful CPA, M.B.A.,
Director of Fin. -
Kevin Laliberte Pharm.D.,
Exec. VP of Product Strategy -
Lori Englebert M.B.A.,
Sr. VP of Commercial & Bus. Devel. -
Dr. Amanda Jones Pharm.D.,
Sr. VP of Clinical Devel. -
Constance Ames,
Vice President, Finance -
Myrtle S Potter,
Director -
Randall Kaye,
Chief Medical Officer -
Hunter R. Murdock,
General Counsel -
John Golubieski,
Chief Financial Officer -
Susan Mahony,